Zhian Sherzad Hayder1,2, Zrar Saleem Kareem3. 1. Department of Basic Science, College of Dentistry, Hawler Medical University, Erbil, Iraq. zhyan.sherzad@hmu.edu.krd. 2. Department of Biology, Faculty of Science and Health, Koya University, KOY45, Kurdistan Region-F.R., Koya, Iraq. zhyan.sherzad@hmu.edu.krd. 3. Department of Biology, Faculty of Science and Health, Koya University, KOY45, Kurdistan Region-F.R., Koya, Iraq.
Abstract
BACKGROUND: Resistin, a potent adipocyte-secreted hormone, may contribute to and modulate iron status and hepcidin level in patients with non-insulin-dependent diabetes mellitus (NIDDM) and end-stage renal disease (ESRD). CONTEXT: The cross-sectional study aimed to determine the possible role of resistin in the iron status pathway in patients with NIDDM and ESRD events are sparse with conflicting results. METHODS: A total of 130 patients and 42 healthy subjects were included in the study and grouped into four none obese groups with normal C-reactive protein (CRP) level: Group 1 (control), Group 2 (NIDDM), Group 3 (ESRD on hemodialysis), and Group 4 (NIDDM + ESRD on hemodialysis). Resistin hormone, ferritin, hepcidin, serum iron, TIBC, and TS% were estimated. RESULTS: Resistin, hepcidin, and ferritin were significantly increased in all groups when compared to control. TIBC significantly increased in ESRD and NIDDM + ESRD when compared to controls. Serum iron and TS% significantly decreased in all groups when compared to controls. Resistin showed a significant positive correlation with hepcidin and ferritin. CONCLUSION: It was determined that serum resistin elevated in patients and correlated directly with hepcidin and ferritin levels. The present finding regarding receiver-operating characteristic curve (ROC curve) analysis of resistin hormone proposed that resistin could be represented as a biomarker for iron dysfunction in NIDDM and ESRD.
BACKGROUND:Resistin, a potent adipocyte-secreted hormone, may contribute to and modulate iron status and hepcidin level in patients with non-insulin-dependent diabetes mellitus (NIDDM) and end-stage renal disease (ESRD). CONTEXT: The cross-sectional study aimed to determine the possible role of resistin in the iron status pathway in patients with NIDDM and ESRD events are sparse with conflicting results. METHODS: A total of 130 patients and 42 healthy subjects were included in the study and grouped into four none obese groups with normal C-reactive protein (CRP) level: Group 1 (control), Group 2 (NIDDM), Group 3 (ESRD on hemodialysis), and Group 4 (NIDDM + ESRD on hemodialysis). Resistin hormone, ferritin, hepcidin, serum iron, TIBC, and TS% were estimated. RESULTS:Resistin, hepcidin, and ferritin were significantly increased in all groups when compared to control. TIBC significantly increased in ESRD and NIDDM + ESRD when compared to controls. Serum iron and TS% significantly decreased in all groups when compared to controls. Resistin showed a significant positive correlation with hepcidin and ferritin. CONCLUSION: It was determined that serum resistin elevated in patients and correlated directly with hepcidin and ferritin levels. The present finding regarding receiver-operating characteristic curve (ROC curve) analysis of resistin hormone proposed that resistin could be represented as a biomarker for iron dysfunction in NIDDM and ESRD.
Entities:
Keywords:
ESRD; Hepcidin; Iron status; NIDDM; Resistin
Authors: D A de Luis; M C Terroba; L Cuellar; R Conde; D Primo; R Aller; M G Sagrado; O Izaola Journal: Horm Metab Res Date: 2011-01-24 Impact factor: 2.936
Authors: Hee-Taik Kang; John A Linton; Soon Kil Kwon; Byoung-Jin Park; Jong Hun Lee Journal: Int J Environ Res Public Health Date: 2016-10-29 Impact factor: 3.390
Authors: Michael Lehrke; Muredach P Reilly; Segan C Millington; Nayyar Iqbal; Daniel J Rader; Mitchell A Lazar Journal: PLoS Med Date: 2004-11-30 Impact factor: 11.069